Geographic Medicine and Infectious Diseases

Back to Results

Michael R. Jordan, MD, MPH

Michael R. Jordan, MD, MPH
Meet Michael R. Jordan, MD, MPH

Title(s)

Director, Tufts Medical Center and Tufts University COVID-19 Biorepository and Comprehensive Database; Attending Physician; Associate Professor of Medicine, Tufts University School of Medicine

Department + Services

Medicine, Geographic Medicine and Infectious Diseases

Clinical Focus Areas

HIV/AIDS, general infectious disease

Research Focus Areas

Dr. Jordan conducts research in SARS CoV-2 infection and HIV drug resistance. He serves as a consultant to the World Health Organization, and is co-chair of the World Health Organization HIV Drug Resistance Surveillance and Epidemiology Working Group and a member of the steering group for the World Health Organization HIV Resistance Network (WHO HIVResNet). Areas of active research include:
• single genome sequencing of SARS CoV2 to identify resistance and host immune response
• impact of sex and gender on COVID-19 outcomes
• SARS CoV-2 surveillance epidemiology
• transdisciplinary research methods
• emerging infectious diseases
• public health policy
• HIV drug resistance
• HIV-1 subtypes and phylogenetic analysis
• Antiretroviral Therapy (ART) optimization in low- and middle-income countries
• point-of-care urine drug level testing and impact on ART adherence in low- and middle-income countries.


Programs + Specialties
Training + Education Tufts University School of Medicine; Tufts Medical Center; Harvard School of Public Health
Board Certifications Infectious Disease, Internal Medicine
NPI # 1679506596
Gender Male
Language(s) French
Accepted Insurances View Accepted Insurances at Tufts Medical Center

1. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008; 13 Suppl 2:15-23.

2. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme A-M, Sandstrom P, Boucher CAB, van de Vijver D, Rhee S-Y, Liu TF, Pillay D, Shafer RW, Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update, PLOS One, (4):3 March 2009.

3. Jordan MR, La H, Nguyen HD, Sheehan H, Lien TT, Duong DV, Hellinger J, Wanke C, Tang AM. Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam Int J STD AIDS. 2009 Jun; 20(6):418-22.

4. Jordan MR, Kearney M, Palmer S, Shao W, Maldarelli F, Coakley EP, Chappey C, Coffin JM, Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. J Virol Methods. 2010 Sep; 168(1-2):114-20.

5. Bertagnolio S, Parkin NT, Jordan MR, Brooks J, Garcia-Lerma, JG. Dried Blood Spots for HIV-1 Drug Resistance and Viral Load Testing: a Review of Current Knowledge and WHO Efforts for Global HIV Drug Resistance Prevention, Aids Reviews. 2010. Oct-Dec; 12(4):195-208.

6. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, Wanke C, Lewin SR, Elliott JH. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring, Clin Infect Dis. 2011 Feb; 52(4):493-506.

7. Jordan MR. Assessment of HIV Drug Resistance Mutations in Resource-Limited Settings. Clin Infect Dis. 2011 April 15. 52 (8): 1058-1060.

8. Tang AM, Sheehan HB, Jordan MR, Duong DV, Terrin N, Dong K, Lien TT, Trung NV, Wanke CA, Hien ND. Predictors of Weight Change in Male HIV-Positive Injection Drug Users Initiating Antiretroviral Therapy in Hanoi, Vietnam. AIDS Res Treat. 2011; 2011:890308. Epub 2011 Jul 6.

9. Jordan MR, Parkin N, Bertagnolio S. Surveillance of transmitted and acquired HIV drug resistance using World Health Organization survey methods in resource limited settings. Antivir Ther. 2011. 16 Suppl1: 41.

10. Wadonda N, Moyo K, Van Oosterhout JJ, Aberle-Grasse J, Warne T, Chilima B, Banda R, Porter C, Weigel R, Kagoli M, Hosseinipour M, Jordan MR, Demby A, Kabuluzi S, Chimbwandira F, Yang C, Bennett DE. Prevalence of HIV drug resistance before treatment initiation and at 12 months after treatment initiation in four sites in the Malawi ART programme. Antivir Ther. 2011. 16 Suppl 1: 131.

11. Yu D, Sutherland D, Ghidinelli M, Jordan MR. Current Status of HIV Drug Resistance Assessment in the Western Pacific Region: A Systematic Review, Aids Reviews. 2011 Oct; 13(4):214-26.

12. Jordan M, Bennett DE, Wainberg M, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing A, Parkin N Nachega JB, Phillips A, Deluca A, Geng E, Calmy A, Raizes E, Sandstrom P, Perriëns J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004 -2011. Clin Infect Dis. 2012; 54(S4):S245–9.

13. Bennett DE, Jordan MR, Bertagnolio S, Hong SY, Mc Mahon J, Kelley K. HIV drug resistance early warning indicators Summary from 50 countries. Clin Infect Dis 2012; 54(S4):S280–9.

14. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012 Oct 6; 380(9849):1250-8.

15. McMahon JH, Elliott JH, Hong SY, Bertagnolio S, Jordan MR. Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review. PLoS One. 2013; 8(2):e56047.

16. McMahon JH, Manoharan A, Wanke CA, Mammen S, Jose H, Malini T, Kadavanu T, Jordan MR, Elliott JH, Lewin SR, Mathai D. Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. AIDS Behav. 2013 Jul; 17(6):2253-9.

17. Hong SY, Jerger L, Jonas A, Badi A, Cohen S, Nachega JB, Parienti JJ, Tang AM, Wanke C, Terrin N, Pereko D, Blom A, Trotter AB, Jordan MR. Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia. PLoS One. 2013; 8(2):e56307.

18. Andersson E, Shao W, Bontell I, Cham F, Cuong do D, Wondwossen A, Morris L, Hunt G, Sönnerborg A, Bertagnolio S, Maldarelli F, Jordan MR. surveys. Infect Genet Evol. 2013 Aug; 18:125-31.

19. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. review. Bull World Health Organ. 2013. May 1; 91(5):377-385E.

20. Trotter AB, Hong SY, Srikantiah P, Abeyewickreme I, Bertagnolio S, Jordan MR. Systematic review of HIV drug resistance in Southeast Asia. Aids Rev. 2013 Jul-Sep; 15(3):162-70.

21. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013 May 1; 91(5):377-385E.

22. Jordan M, Obeng-Aduasare Y, Sheehan H, Hong S, Terrin N, Duong D, Trung N, Wanke C, Kinh N, Tang A. Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS. 2013 Dec 18.

23. Jordan MR, Winsett J, Tiro A, Bau V, Berbara R, Rowley C, Bellosillo N, Wanke C, Coakley EP, HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels, World Journal of AIDS, Vol. 3 No. 2, 2013, 1-78.

View all Dr. Jordan's publications on PubMed.